Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE102 in healthy and overweight/obese subjects
NCT06493084Phase 1Recruiting
- Sponsor
- Laekna
- Start
- Jun 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LAE102 in obesity (6 arms), sponsored by Laekna. Primary endpoint: Adverse Events. Started Jun 2024; status: recruiting.
02
Drugs
LAE102
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06493084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06493084.